Cerebrolysin: what does this study show?
Randomized, double-blind trial after stroke: 30 mL daily or saline for 21 days, starting 24–72 hours after stroke, alongside rehabilitation. Sample size and route are not stated in the abstract.
The primary arm-function score at day 90 favored Cerebrolysin. Global outcomes also favored treatment, and reported safety was comparable with placebo.
The authors describe an exploratory, relatively small study requiring larger confirmation. Stroke rehabilitation findings do not establish cognitive enhancement in healthy people.
These findings apply to the population and methods described above.
What might this mean, and what would change the interpretation?
The authors describe an exploratory, relatively small study requiring larger confirmation. Stroke rehabilitation findings do not establish cognitive enhancement in healthy people.
What would clarify this: Independent replication with clinically meaningful outcomes and longer safety follow-up.
Findings reviewed · abstract
Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.